The value and strategy for incorporating biosimilars Into clinical practice

Bookmark and Share
Published: 7 Jun 2016
Views: 4329
Dr Francisco Esteva - New York University, New York, USA

Dr Esteva speaks with ecancertv at ASCO 2016 about biosimilars, an emerging class of therapeutic agents with similar activity to known therapies, yet distinct molecular arragements.

He summarises the definition and construction of a biosimilar, how these might be incorporated into wider clinical practice, and regulatory issues in setting a biosimilar apart from its analogue therapeutics.

A trastuzumab biosimilar is the focus of research by Dr Hope Rugo, whose interview is available here.

ecancer's filming at ASCO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.